About the Study

RSV, Respiratory Syncytial Virus, is a very common, highly contagious virus that causes infection of the respiratory tract in people of all ages. In the Rochester climate, symptoms usually develop during fall and winter, however, the time of year can depend on other viruses circulating in the area. In many people, the disease is quite mild and can produce cold-like symptoms. However, in older adults, and people with chronic diseases such as COPD or asthma, it can be very serious and result in hospitalization or death. There is currently no vaccine available to the general public to prevent this infection and antibiotics are not helpful as this infection is viral.

RCR will be conducting an RSV vaccine study to test the efficacy of a vaccine that may protect against lower respiratory tract disease, which is associated with the RSV virus. The study will last about 24 to 30 months and consists of  up to 6 office visit and a monthly telephone appointment. Compensation is available for time and travel to participate in the study. 

Study-related care is available to participants at no cost and health insurance is not required nor needed. If you are interested in joining the RSV vaccine study at RCR, call 585-288-0890.

Qualifications

  • 64+ years
  • If you have chronic conditions (COPD, Asthma) are they stable?
  • Willing to come in for nasal swabs if symptoms appear.
  • Able to use an electronic device for diaries
  • *Please note, that other conditions may apply.